AD/PD™ 2022 brings a new look and a new chapter in the history of the AD/PD™ series of conferences. By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now transformed into an annual meeting, with a continuing focus on the ADVANCES IN SCIENCE & THERAPY of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
A NEW CHAPTER IN THE HISTORY OF AD/PD™
We are excited to provide improved opportunities for international medical and scientific professionals to come together and discuss the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
A central theme of the 2022 conference will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.
AD/PD™ 2022 will be held as a hybrid conference, giving you the option to attend either virtually, or physically in Barcelona. Click here to find out more about the different registration options available.
WARNING
There is an increasing number of fraudulent websites that are attempting to impersonate AD/PD™. Use only trusted online registration services. For the Conference registration form click here. For the official hotel booking system click here.
Cutting-Edge Science
The AD/PD™ conference offers a high quality scientific program covering the most recent research, clinical trials, developments, and treatments in Alzheimer’s and Parkinson’s, with emphasis on overlaps and congruent results among AD. This provides participants with unparalleled and powerful insights into distinct neurodegenerative diseases in one setting to examine their similarities and differences.
Top Speakers in the Field
Science and education are the main forces behind AD/PD™ conferences and participants agree that the quality of the content and the educational value are what set it apart from other events in the field. In the 2019 CME Participant evaluation form 96% state that the event contributed to their professional development, while almost 97% agree that the quality of the speakers was excellent.
AD/PD™ in Numbers
A unique conference that provides a world class platform for clinical investigators and basic scientists to present, discuss and trade expertise on a broad range of themes and topics, AD/PD™ has gone from strength to strength attracting over 3,800 participants from 75 countries and over 2,200 abstracts.
AD/PD™ Education
Learn MoreNeurodegenerative Disease Professional
